Analyst Price Targets — EFTR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 4, 2024 1:27 pm | — | Stifel Nicolaus | $10.00 | $2.96 | StreetInsider | eFFECTOR Therapeutics, Inc. (EFTR) PT Lowered to $10 at Stifel |
| January 9, 2023 8:10 am | — | JMP Securities | $1.00 | $0.44 | Benzinga | JMP Securities Maintains Market Outperform on eFFECTOR Therapeutics, Lowers Price Target to $1 |
Latest News for EFTR
Comparing eFFECTOR Therapeutics (NASDAQ:EFTR) and Orgenesis (NASDAQ:ORGS)
Volatility and Risk eFFECTOR Therapeutics has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 3.44, suggesting that its stock price is 244% more volatile than the S&P 500. Earnings and Valuation This table compares eFFECTOR Therapeutics and Orgenesis"s gross revenue,
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EFTR.
U.S. House Trading
No House trades found for EFTR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.